Neoplasm Metastasis
122 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Neoplasms
Narrower: Neoplasms, Unknown Primary 2, Neoplastic Cells, Circulating 3
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 186RNL for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Abemaciclib for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Abemaciclib + Irinotecan + Temozolomide for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ablative Prostate Boost + Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anastrozole placebo + Letrozole placebo + CAMIZESTRANT for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Higher Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Androgen Deprivation Therapy (ADT) + Androgen Receptor Pathway Inhibitors (ARPIs) + Intermediate Nodal Dose Escalation + SBRT-Based Prostate Radiotherapy (No Boost) + Ultrahypofractionated Whole-Pelvis Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ART6043 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ART6043 + Olaparib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ASP3082 for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atezolizumab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATEZOLIZUMAB + Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AVB-001 (Dose Escalation Phase) + AVB-001 (Dose Expansion Phase) for neoplasm metastasis | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Axelopran + pembrolizumab for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BEVACIZUMAB + Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biopsy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Multigated Acquisition Scan + Radiologic Imaging Procedure + PIDNARULEX + TRASTUZUMAB DERUXTECAN for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Capecitabine for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Capecitabine + pembrolizumab for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Capivasertib for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin + ELRAGLUSIB + Paclitaxel for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin-Paclitaxel for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cisplatin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Questionnaire Administration + Psilocybin for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CP-383 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CR-002 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Daraxonrasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Datopotamab Deruxtecan for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Digoxin for neoplastic cells, circulating | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Divarasib + Cetuximab for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Divarasib + ERLOTINIB for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Divarasib + Inavolisib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dostarlimab for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doublet Chemotherapy, Dose-reduced (75%) for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doxorubicin hydrochloride + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DURVALUMAB + Datopotamab Deruxtecan for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography Test + Doxorubicin hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elironrasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elironrasib + Daraxonrasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elraglusib for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELRAGLUSIB + Gemcitabine Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ENABLE Cornerstone for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FMC-376 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Folfoxiri for neoplastic cells, circulating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fulvestrant + CDK4/6i + Capivasertib for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gemcitabine Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-102 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-102 + BEVACIZUMAB + Paclitaxel for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-102 + Doxorubicin for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-102 + Eribulin for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-102 + PEMBROLIZUMAB for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-102 + TRASTUZUMAB DERUXTECAN for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-102 subcutaneous (SC) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GI-108 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hafnium Oxide-containing Nanoparticles NBTXR3 + Radiation Therapy for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hybrid Palliative Radiation Therapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Irinotecan + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Irinotecan + Temozolomide for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Irinotecan hydrochloride + bevacizumab for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IRINOTECAN HYDROCHLORIDE + BEVACIZUMAB + LEUCOVORIN + Fluorouracil for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Iscador*P for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivonescimab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Local Therapy + Standard Therapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Loco-regional radiotherapy for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lomustine + ELRAGLUSIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Migoprotafib + Divarasib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ML-016 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Molecularly matched therapy for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Monotherapy, Dose-reduced (75%) for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| N17350 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nab-paclitaxel for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nab-paclitaxel + Gemcitabine + VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neoadjuvant chemotherapy instead of upfront surgery for neoplastic cells, circulating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NIMOTUZUMAB + Ivonescimab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Niraparib for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nivolumab & Ipilimumab + Zirdafulven for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NSAI + CDK4/6i + Capivasertib for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oleclumab for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OR502 + CEMIPLIMAB for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OSIMERTINIB + Patritumab Deruxtecan for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Osimertinib + Savolitinib for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Paclitaxel for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Panitumumab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Patritumab Deruxtecan for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PD-1 Inhibitors + Mitoxantrone Hydrochloride for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PD1+ TILs (NUMARZU-001) product infusion for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pembrolizumab for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEMBROLIZUMAB + Paclitaxel for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PET/CT + FLUDEOXYGLUCOSE F-18 + [18F]-FAPI-74 for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ponsegromab for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| prifetrastat in combination with fulvestrant for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| prifetrastat monotherapy for 15 days then combination with fulvestrant for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prophylactic External Beam Radiotherapy for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + Survey Administration + Psilocybin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Puxitatug Samrotecan for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| S-1 + Irinotecan for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sacituzumab tirumotecan for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Savolitinib + Placebo for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sbrt for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Spartalizumab for neoplasms, unknown primary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Telisotuzumab vedotin for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tersolisib for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tislelizumab for neoplasms, unknown primary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trametinib + Doxorubicin + CISPLATIN + Gefitinib + Disulfiram + SUNITINIB + Methotrexate for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trametinib + Gefitinib + Disulfiram + Ifosfamide + SUNITINIB for neoplasm metastasis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trastuzumab deruxtecan for neoplasm metastasis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TYRA-300 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 100 mg Tablet for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VMD-928 Tablet and Pembrolizumab (200 mg) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xiaochaihu Granules (Low Dose) for neoplasm metastasis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| XON7 for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zidesamtinib (NVL-520) for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zirdafulven for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zirdafulven + Olaparib for neoplasm metastasis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.